Pemetrexed · Non-small cell lung cancer · Skin toxicity · Toxic epidermal necrolysis Summary Background: Pemetrexed is an antifolate drug approved for maintenance and second-line therapy, and, in combination with cisplatin, for first-line treatment of advanced nonsquamous non-small cell lung cancer. The side-effect profile includes fatigue, hematological and gastrointestinal toxicity, an increase in hepatic enzymes, sensory neuropathy, and pulmonary and cutaneous toxicity in various degrees. Case Report: We present the case of a 58-year-old woman with history of Sharp's syndrome and adenocarcinoma of the lung, who developed toxic epidermal necrolysis after the first cycle of pemetrexed, including erythema, bullae, extensive skin denudation, subsequent systemic inflammation and severe deterioration in general condition. The generalized skin lesions occurred primarily in the previous radiation field and responded to immunosuppressive treatment with prednisone. Conclusion: Although skin toxicity is a wellknown side effect of pemetrexed, severe skin reactions after pemetrexed administration are rare. Caution should be applied in cases in which pemetrexed is given subsequent to radiation therapy, especially in patients with pre-existing skin diseases.
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Introduction
Afterintracellularmetabolizationtoapentaglutamateform, pemetrexed inhibits thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide transferase, all involvedinfolatemetabolism,thusblockingboththepurine and pyrimidine pathways of DNA synthesis [1] . In 2008, a combination of pemetrexed with cisplatin was approved by the European Medicines Agency and the US Food and Drug Administration for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with other than squamous cell histology. This combination has been tested in phase III clinical trials, and has shown promising antitumor activitywithagenerallymildtoxicityprofile [2] [3] [4] .Themost common adverse events with a frequency of more than 5% arehematological(neutropeniagrade3-4in25%ofpatients), gastrointestinal and hepatic toxicity, fatigue, sensory neuropathy and skin reactions [2] [3] [4] [5] . Cutaneous toxicity has been reportedin10-22%ofpatients,usuallyasagrade1-2rashor periorbitalandlimbedema,butalsoinvariousotherforms, such as diffuse hyperpigmentation, urticarial vasculitis and generalized exanthematous pustulosis [3, [5] [6] [7] [8] . Nevertheless, to our knowledge, toxic epidermal necrolysis (TEN) related to pemetrexed has been described in only 2 other cases to date [9, 10] .
Case Report
A 58-year-old woman was diagnosed with adenocarcinoma of the lung stageIIIbwithnegativeEGFRmutationalstatusinMarch2011.Thepatient was a current smoker. There was no medical history apart from Sharp'ssyndrome,diagnosedin2003andtreatedwith2mgprednisone daily and 15 mg methotrexate weekly. Beside an initial Raynaud's phenomenon and occasional palmar and plantar erythema, no other skin lesionswereassociatedwiththeSharp'ssyndrome.Thepatientreceived 2 cycles of chemotherapy with cisplatin (20 mg/m 2 days 1-4) andvino relbine(50mg/m 2 days1,8and15)andsimultaneousradiation therapyoftheprimarytumorofthemiddlelobeandinfracarinallymph node metastaseswithanoveralldoseof64Gy.After2cyclesofchemo-therapy and completion of the radiation therapy, a PET-CT scan was performed,whichrevealedpartiallocaltumorresponse,butalso2brain metastases. Due to these findings, the chemotherapy was switched to cisplatin (75 mg/m 2 day 1) and pemetrexed (500 mg/m 2 day 1), which wasadministered26daysafterthecompletionoftheradiationtherapy. Supplementation with 5 mg folic acid daily orally and 1 mg vitamin B12 monthly subcutaneously was each started 7 days prior to cisplatin/ pemetrexed.Afterdetectionofthebrainmetastasesand15daysbefore the administration of cisplatin/pemetrexed, the patient received 12 mg dexamethasonedaily.Nootherdrugswerestarted.
Twodaysafterthefirstcycleofcisplatinandpemetrexed,thepatient presented a generalized pruritic rash, primarily involving the radiation sitesatthechestwall,butalsothearms,legsandface,especiallythelips. Within3days,theinitiallysmallerythematousmaculesaggravated,forminglargebullaecontainingclearliquidandleadingtodesquamationwith large areas of epidermal detachment and multiple bleeding wounds ( fig. 1A and B) . As in a previously reported case of TEN after pemetrexedapplication [9] ,wedetectednosignofmucosalorocularinvolvement.Skinbiopsyrevealedkeratinocyteapoptosis,epidermalseparation at a sub-epidermal level and overlying extensive epidermal necrosis. A scanty lymphocytic infiltrate was visible in the dermis (fig. 1C) . On the dayoftheonsetoftherash,thehemoglobinlevelwas8.6g/dl,theplatelet count226×10 9 /landthewhitebloodcellcount4.3×10 9 cells/lwith71% polymorphonuclearleukocytes.FurtherlaboratorytestsrevealedC-reactiveprotein(CRP)of2.1mg/dl(<0.5mg/dl)andlactatedehydrogenase (LDH)of193U/l(>250U/l).
Immunosuppressive treatment with 75 mg prednisone daily intravenously was started on the day that the rash appeared and 180 mg f exofenadine 3 times daily orally was added 3 days later. Topical treatmentwasperformedwithapotentsteroidcream(betamethasonedipropionate,0.64mg/g).
The total white blood cell count dropped to 0.4 × 10 9 cells/l 2 days after the onset of the rash and granulocyte-colony stimulating factor treatment (30 million units filgrastim daily) was started. Neutropenia lasted for 3 days and the patient required 4 erythrocyte and 2 platelet transfusionstomaintainahemoglobinlevelabove8.0g/dlandaplatelet countabove10×10 9 /l.Antibiotictreatmentwithpiperacillin-tazobactam was started after the laboratory inflammation signs increased, and the prednisonedosewasdecreasedto50mgdaily5daysaftertheonsetof therash.Subsequently,prednisonewastaperedoverthefollowingweeks andwasreplacedbythepreviousmedicationdexamethasone.
CRPandLDH,whichmayalsobeprognosticparameters [11] ,roseto amaximumof29mg/dland265U/l6daysaftertherashdevelopment. Thepatientexperiencedaseveredeteriorationofgeneralhealth,including fever and staphylococcal septicemia. The skin lesions were painful and continuous morphine application was necessary. Due to severe involvementofthelips,totalparenteralnutritionwasnecessaryforseveral days.AccordingtotheSCORTENseverity-of-illnessscore [12] ,predicted mortalitywas36%.Thefirstsignofimprovementoftheskinlesionswas 
Discussion
TEN is a severe epidermolytic reaction with an incidence of 1-2 cases per million in the western population [13] . It is associated with drugs, especially allopurinol, antibiotics and anticonvulsants,orlessfrequently,withbacterialorviralinfections,suchasmycoplasmapneumonia,herpessimplexand HIV.Inrarecases,theetiologyremainsunknown [13] [14] [15] .
Aggravatingfactorsinthepatientpresentedheremayhave been the previous radiotherapy, chemotherapy-induced neutropenia, and the pre-existing Sharp's syndrome. The most severe skin lesions occurred in the previous radiation field.Althoughthepatienthadnovisibleskinirritationinthe radiation field prior to the administration of pemetrexed, and the last radiation therapy had been applied 26 days before the onset of the rash, a pre-existing skin irritation may haveworsenedtheproblem.Radiation-recalldermatitisafter pemetrexedapplicationhasbeendescribedafteratimeintervalaslongas27yearsfollowingradiationtherapy [16] ,with attemptedexplanationssuggestingstem-celldepletionand/or mutations as well as local vascular damage causing a diminishedskinrecoverypotentialintheradiotherapyfield.Independentlyoftheuseofpemetrexed,radiotherapyortheexistenceofcancerhasbeenshowntohaveanimpactonTENincidence [13, 17] .Ontheotherhand,acombinationofradiationtherapywithpemetrexeduptothedoseof600mg/m 2 has beenreportedwithoutmajorskinreactioninaphaseIstudy [18] ,andearlysitesofcutaneousinvolvementaretypicallythe presternal region and the face [13] , and may coincidentally matchwiththeradiationfieldinourpatient.
The aggravation of the skin lesions converged with the onsetofneutropenia.The2previouslyreportedcasesofTEN after pemetrexed administration were also both associated withpancytopenia,althoughnotstrictlyspeakingneutropenia [8, 9] . Pathogenically, TEN is thought to be a specific drug hypersensitivityreaction [13] .CytotoxicTlymphocytesanda lossoffunctionofCD4 + CD25 + regulatoryTcellsmayplaya majorroleintheinitiationphase [13, 19] .Therefore,immunosuppressionorimmunomodulationcausedbydifferentconditions, such as chemotherapy or AIDS (the latter increasing the risk 1,000-fold [15] ), could facilitate the development of TENbysuppressingregulatoryTcells.Additionally,neutropeniaisageneralriskfactorforinfection,includingbacterial infectionsofaffectedskin,anditisconceivablethatduetoan alteredcytokineenvironmentitmayalsorestrainthehealing process.
Sharp's syndrome is a mixed connective tissue disorder withfrequentskininvolvementcharacterizedbyvascularlesions, such as intimal proliferation and medial hypertrophy, primarily affecting small vessels and becoming manifest in a Raynaud's phenomenon, swollen hands and puffy fingers or scleroderma-likevasculopathy [20] .Eventhoughvisiblecutaneousmanifestationsareoftenrestrictedtohandsandfeet,as inthepatientdescribedhere,Sharp'ssyndromeisasystemic disease and the underlying vascular alterations may also be presentinotherskinareas,theoreticallypromotingcutaneous lesionscausedbydifferentagents.
Because of its potential fatality, TEN is a medical emergency.ThehighmorbidityandmortalityofTENiscausednot leastbyitsrarityandtheunderestimationofitsseverity.Initial small and inconspicuous maculae rapidly develop into TENandthepatientmayrequireintensivecare.Therefore,it iscrucialtostoptheallegedcausingagentimmediatelyandto assure the diagnosis. The most serious problem, however, is thelackofanestablishedstandardtreatment.DuetotherarityofTEN,randomizedcontrolledtrialsassessingtheefficacy ofdifferenttreatmentoptionsdonotexist,andmanycasereportslackimportantinformationaboutresponsetotreatment and time of hospitalization [21] . The use of corticosteroids, high-dose intravenous immunoglobulin and other immunosuppressive therapies remains controversial and has proved noclearbenefitcomparedtosupportivetreatmentalone [13, 22, 23] . Especially if septicemia is present, as often occurs whenlargeskinareasaredenuded,immunosuppressionmay herald the possibility of an exacerbation of the infection. Nevertheless,mostauthorscurrentlyfavourtheuseofcorticosteroidsorintravenousimmunoglobulin [13, 15, 21] .Prednisone was started at the day of the first emergence of the rash in the patient described here, but was not successful in preventing severe skin detachment. However, as in the 2 othercasesofTENafterpemetrexed,whichwerealsotreated withsystemicsteroids [8, 9] ,theoutcomeforthepatientwas favorable.
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